6z06: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==== | ==Crystal structure of Puumala virus Gc in complex with Fab 4G2== | ||
<StructureSection load='6z06' size='340' side='right'caption='[[6z06]]' scene=''> | <StructureSection load='6z06' size='340' side='right'caption='[[6z06]], [[Resolution|resolution]] 3.50Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[6z06]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Myodes_glareolus Myodes glareolus] and [https://en.wikipedia.org/wiki/Puumala_orthohantavirus Puumala orthohantavirus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6Z06 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6Z06 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.5Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6z06 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6z06 OCA], [https://pdbe.org/6z06 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6z06 RCSB], [https://www.ebi.ac.uk/pdbsum/6z06 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6z06 ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Function == | |||
[https://www.uniprot.org/uniprot/Q9WJ31_9VIRU Q9WJ31_9VIRU] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The intricate lattice of Gn and Gc glycoprotein spike complexes on the hantavirus envelope facilitates host-cell entry and is the primary target of the neutralizing antibody-mediated immune response. Through study of a neutralizing monoclonal antibody termed mAb P-4G2, which neutralizes the zoonotic pathogen Puumala virus (PUUV), we provide a molecular-level basis for antibody-mediated targeting of the hantaviral glycoprotein lattice. Crystallographic analysis demonstrates that P-4G2 binds to a multi-domain site on PUUV Gc and may preclude fusogenic rearrangements of the glycoprotein that are required for host-cell entry. Furthermore, cryo-electron microscopy of PUUV-like particles in the presence of P-4G2 reveals a lattice-independent configuration of the Gc, demonstrating that P-4G2 perturbs the (Gn-Gc)(4) lattice. This work provides a structure-based blueprint for rationalizing antibody-mediated targeting of hantaviruses. | |||
Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein.,Rissanen I, Stass R, Krumm SA, Seow J, Hulswit RJ, Paesen GC, Hepojoki J, Vapalahti O, Lundkvist A, Reynard O, Volchkov V, Doores KJ, Huiskonen JT, Bowden TA Elife. 2020 Dec 22;9:e58242. doi: 10.7554/eLife.58242. PMID:33349334<ref>PMID:33349334</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6z06" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
*[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: | [[Category: Myodes glareolus]] | ||
[[Category: Puumala orthohantavirus]] | |||
[[Category: Bowden TA]] | |||
[[Category: Doores KJ]] | |||
[[Category: Hepojoki J]] | |||
[[Category: Huiskonen JT]] | |||
[[Category: Hulswit RJG]] | |||
[[Category: Krumm SA]] | |||
[[Category: Lundkvist A]] | |||
[[Category: Paesen GC]] | |||
[[Category: Reynard O]] | |||
[[Category: Rissanen IR]] | |||
[[Category: Seow J]] | |||
[[Category: Stass R]] | |||
[[Category: Vapalahti O]] | |||
[[Category: Volchkov V]] | |||
Latest revision as of 16:39, 24 January 2024
Crystal structure of Puumala virus Gc in complex with Fab 4G2Crystal structure of Puumala virus Gc in complex with Fab 4G2
Structural highlights
FunctionPublication Abstract from PubMedThe intricate lattice of Gn and Gc glycoprotein spike complexes on the hantavirus envelope facilitates host-cell entry and is the primary target of the neutralizing antibody-mediated immune response. Through study of a neutralizing monoclonal antibody termed mAb P-4G2, which neutralizes the zoonotic pathogen Puumala virus (PUUV), we provide a molecular-level basis for antibody-mediated targeting of the hantaviral glycoprotein lattice. Crystallographic analysis demonstrates that P-4G2 binds to a multi-domain site on PUUV Gc and may preclude fusogenic rearrangements of the glycoprotein that are required for host-cell entry. Furthermore, cryo-electron microscopy of PUUV-like particles in the presence of P-4G2 reveals a lattice-independent configuration of the Gc, demonstrating that P-4G2 perturbs the (Gn-Gc)(4) lattice. This work provides a structure-based blueprint for rationalizing antibody-mediated targeting of hantaviruses. Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein.,Rissanen I, Stass R, Krumm SA, Seow J, Hulswit RJ, Paesen GC, Hepojoki J, Vapalahti O, Lundkvist A, Reynard O, Volchkov V, Doores KJ, Huiskonen JT, Bowden TA Elife. 2020 Dec 22;9:e58242. doi: 10.7554/eLife.58242. PMID:33349334[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||